Page last updated: 2024-10-16
carbamates and Cataleptic Attacks
carbamates has been researched along with Cataleptic Attacks in 2 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " Common adverse events (headache, nausea, decreased appetite, and nasopharyngitis) were similar between cataplexy subgroups." | 2.94 | Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. ( Black, J; Carter, LP; Chen, D; Dauvilliers, Y; Emsellem, H; Lammers, GJ; Lee, L; Mayer, G; Plazzi, G; Shapiro, C; Thorpy, MJ, 2020) |
| "Narcolepsy is the most common cause of excessive daytime sleepiness (EDS) following obstructive sleep apnea." | 2.66 | [Advances in treatment of narcolepsy]. ( Lou, G; Wang, T; Xu, Q; Zhang, L, 2020) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Dauvilliers, Y | 1 |
| Shapiro, C | 1 |
| Mayer, G | 1 |
| Lammers, GJ | 1 |
| Emsellem, H | 1 |
| Plazzi, G | 1 |
| Chen, D | 1 |
| Carter, LP | 1 |
| Lee, L | 1 |
| Black, J | 1 |
| Thorpy, MJ | 1 |
| Xu, Q | 1 |
| Lou, G | 1 |
| Wang, T | 1 |
| Zhang, L | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy[NCT02348593] | Phase 3 | 239 participants (Actual) | Interventional | 2015-05-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in ESS Score From Baseline to Week 12
"Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness.~The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline." (NCT02348593)
Timeframe: Baseline to Week 12
| Intervention | points on a scale (Least Squares Mean) |
|---|
| Placebo | -1.6 |
| 75 mg of JZP-110 | -3.8 |
| 150 mg JZP-110 | -5.4 |
| 300 mg of JZP-110 | -6.4 |
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12
Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing. (NCT02348593)
Timeframe: Baseline to Week 12
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | 2.12 |
| 75 mg of JZP-110 | 4.74 |
| 150 mg JZP-110 | 9.77 |
| 300 mg of JZP-110 | 12.27 |
Change in Sleep Latency Time on MWT Trial 1 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12. (NCT02348593)
Timeframe: Change from baseline for sleep latency in MWT during trial 1 at week 12
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | -0.55 |
| 75 mg of JZP-110 | 3.27 |
| 150 mg JZP-110 | 9.87 |
| 300 mg of JZP-110 | 9.91 |
Change in Sleep Latency Time on MWT Trial 2 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12. (NCT02348593)
Timeframe: Change from baseline for sleep latency in MWT during trial 2 at week 12
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | 1.41 |
| 75 mg of JZP-110 | 5.70 |
| 150 mg JZP-110 | 9.46 |
| 300 mg of JZP-110 | 14.50 |
Change in Sleep Latency Time on MWT Trial 3 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12. (NCT02348593)
Timeframe: Change from baseline for sleep latency in MWT during trial 3 at week 12
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | 3.79 |
| 75 mg of JZP-110 | 6.35 |
| 150 mg JZP-110 | 11.31 |
| 300 mg of JZP-110 | 13.99 |
Change in Sleep Latency Time on MWT Trial 4 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12. (NCT02348593)
Timeframe: Change from baseline for sleep latency in MWT during trial 4 at week 12
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | 2.33 |
| 75 mg of JZP-110 | 3.77 |
| 150 mg JZP-110 | 9.77 |
| 300 mg of JZP-110 | 13.50 |
Change in Sleep Latency Time on MWT Trial 5 at Week 12
Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12. (NCT02348593)
Timeframe: Change from baseline for sleep latency in MWT during trial 5 at week 12
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | 3.09 |
| 75 mg of JZP-110 | 3.92 |
| 150 mg JZP-110 | 9.25 |
| 300 mg of JZP-110 | 12.20 |
Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4
Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from Baseline to Week 4. (NCT02348593)
Timeframe: Baseline to Week 4
| Intervention | minutes (Least Squares Mean) |
|---|
| Placebo | 2.16 |
| 75 mg of JZP-110 | 4.67 |
| 150 mg JZP-110 | 9.15 |
| 300 mg of JZP-110 | 13.07 |
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12
Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse (NCT02348593)
Timeframe: Baseline to Week 12
| Intervention | percentage of subjects (Number) |
|---|
| Placebo | 39.7 |
| 75 mg of JZP-110 | 67.8 |
| 150 mg JZP-110 | 78.2 |
| 300 mg of JZP-110 | 84.7 |
Reviews
1 review available for carbamates and Cataleptic Attacks
Trials
1 trial available for carbamates and Cataleptic Attacks